Coronary heart disease (CHD) remains the leading cause of death in the United States, but the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. Cardio Diagnostics Holdings (NASDAQ: CDIO) reports that approximately 50% of individuals with coronary heart disease do not present with traditional risk factors, and conventional risk calculators have an average sensitivity of 39%. In practical terms, that means many who “look healthy” go on to have CHD and preventable cardiac events such as a heart attack.
For decades, cardiovascular risk assessment has centered on a checklist of factors never designed to capture the full biological picture of how heart disease develops. Healthcare providers ask about cholesterol levels, blood pressure, smoking history, diabetes status, family history and weight. While these factors matter and are useful pieces of the puzzle, they were never designed to capture the full molecular picture. What makes CHD numbers particularly troubling is that so much of this is preventable.
Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics fields that examine how genes are expressed and regulated at the molecular level. By moving beyond traditional risk factors, these tests aim to identify CHD in individuals who would otherwise be missed by standard screening methods. For patients and healthcare providers, this means a potential shift from reactive care—waiting for symptoms or a cardiac event—to proactive, precision-based detection.
The implications for the healthcare industry are significant. If adopted widely, molecular precision testing could redefine risk stratification, reduce the number of undiagnosed cases, and ultimately lower the mortality rate associated with CHD. For business leaders, particularly those in health insurance, employer wellness programs, and healthcare systems, this technology offers a path to more efficient resource allocation and better patient outcomes. The ability to detect CHD earlier in asymptomatic individuals could lead to substantial cost savings by preventing expensive emergency interventions and hospitalizations.
Forward-looking statements in the release highlight the potential but also caution that results may differ materially due to risks and uncertainties. The company’s full terms of use and disclaimers are available on the InvestorBrandNetwork website. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.
As the healthcare landscape increasingly embraces personalized medicine, Cardio Diagnostics’ approach represents a step toward closing the diagnostic gap in CHD. For the average patient, this means a better chance of catching heart disease before it becomes a crisis. For the industry, it signals a move away from one-size-fits-all risk calculators toward a more nuanced, biologically informed standard of care.
